Similarly, small-molecule inhibitors that achieve cancer suppression by inhibiting HuR nuclear-cytoplasmic transport include YM-155 [188], MPT0B098 [189], SP600125 [190], AZA and TSA [191], N-benzylcantharidinamide [192], triptolide [193], latrunculin A [194], blebbistatin [194], which are effective in chronic myeloid leukemia [188], lung adenocarcinoma [189], breast cancer [190,191], HCC [192,194], and NSCLC [193]. Here, ELAVL1 is linked to hepatocellular carcinoma.